Get the Stockscreener App
108.88
0.32%
-0.35
Glaukos Corporation stock is traded at $108.88, with a volume of 468.71K.
It is down -0.32% in the last 24 hours and up +17.57% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$109.23
Open:
$108.96
24h Volume:
468.71K
Relative Volume:
0.42
Market Cap:
$6.25B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-36.78
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
+0.34%
1M Performance:
+17.57%
6M Performance:
+11.56%
1Y Performance:
-22.41%
1-Day Range:
$108.45
$110.37
1-Week Range:
$105.88
$110.87
52-Week Range:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
108.88 | 6.27B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos Corporation $GKOS Shares Purchased by Holocene Advisors LP - MarketBeat
Gilder Gagnon Howe & Co. LLC Decreases Position in Glaukos Corporation $GKOS - MarketBeat
Eventide Asset Management LLC Sells 70,181 Shares of Glaukos Corporation $GKOS - MarketBeat
Braidwell LP Has $62.33 Million Stake in Glaukos Corporation $GKOS - MarketBeat
Gilbert Kliman Sells 5,000 Shares of Glaukos (NYSE:GKOS) Stock - MarketBeat
Citigroup Maintains Glaukos (GKOS) Buy Recommendation - Nasdaq
Glaukos Corporation $GKOS Shares Bought by Osterweis Capital Management Inc. - MarketBeat
FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment - MSN
GKOS: Citigroup Raises Glaukos Price Target to $125, Maintains B - GuruFocus
Glaukos price target raised to $125 from $113 at Citi - TipRanks
Invesco Ltd. Sells 455,024 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Sold by Russell Investments Group Ltd. - MarketBeat
Glaukos stock price target raised to $125 from $117 at Needham By Investing.com - Investing.com South Africa
Needham Raises Price Target for GKOS, Maintains Buy Rating | GKO - GuruFocus
Trading the Move, Not the Narrative: (GKOS) Edition - news.stocktradersdaily.com
Glaukos price target raised to $125 from $117 at Needham - TipRanks
Needham Adjusts Glaukos Price Target to $125 From $117, Maintains Buy Rating - marketscreener.com
Glaukos stock price target raised to $125 from $117 at Needham - Investing.com Australia
Marshall Wace LLP Sells 114,086 Shares of Glaukos Corporation $GKOS - MarketBeat
Divisadero Street Capital Management LP Invests $10.51 Million in Glaukos Corporation $GKOS - MarketBeat
Glaukos (NYSE:GKOS) shareholders have earned a 34% CAGR over the last three years - Yahoo Finance
What market sentiment indicators show for Glaukos Corporation stockJuly 2025 Trends & Community Consensus Trade Alerts - Newser
Can Glaukos Corporation stock attract analyst upgradesJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - Newser
Norges Bank Takes $76.31 Million Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC - MarketBeat
Glaukos Corporation Stock Analysis and ForecastMACD Trading Signals & Rapid Portfolio Expansion - earlytimes.in
Why Glaukos Corporation stock appears on watchlistsWeekly Trade Review & Daily Chart Pattern Signal Reports - Newser
Will Glaukos Corporation (6GJ) stock remain on Wall Street radarJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - Newser
Can Glaukos Corporation (6GJ) stock double in coming yearsForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
Is Glaukos Corporation stock a top hedge fund pick2025 Support & Resistance & Short-Term High Return Ideas - Newser
Transcript : Glaukos Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01 - marketscreener.com
Granite Investment Partners LLC Has $19.89 Million Stake in Glaukos Corporation $GKOS - MarketBeat
How higher bond yields impact Glaukos Corporation stockMarket Performance Report & High Accuracy Trade Alerts - Newser
Will Glaukos Corporation (6GJ) stock profit from automation waveBreakout Watch & Safe Capital Investment Plans - Newser
Here's Why You Should Retain Glaukos Stock in Your Portfolio - Your Wyoming Link
New York State Common Retirement Fund Increases Stock Position in Glaukos Corporation $GKOS - MarketBeat
Can Glaukos Corporation stock stage a strong rebound this quarter2025 Valuation Update & Fast Exit Strategy with Risk Control - Newser
Glaukos Corporation $GKOS Shares Purchased by Prudential Financial Inc. - MarketBeat
JPMorgan Chase & Co. Buys 59,389 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Sold by Loomis Sayles & Co. L P - MarketBeat
Legal & General Group Plc Boosts Holdings in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Purchased by Rhumbline Advisers - MarketBeat
Will Glaukos Corporation stock gain from government policies2025 Investor Takeaways & Entry and Exit Point Strategies - BỘ NỘI VỤ
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue? - Yahoo Finance
(GKOS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Handelsbanken Fonder AB Reduces Holdings in Glaukos Corporation $GKOS - MarketBeat
Creative Planning Has $1.90 Million Stock Holdings in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corporation $GKOS Shares Purchased by Atika Capital Management LLC - MarketBeat
Alex Thurman Sells 315 Shares of Glaukos (NYSE:GKOS) Stock - MarketBeat
Why Glaukos (GKOS) Is Up 13.9% After iDose Tops Forecasts and 2025 Outlook Rises - simplywall.st
Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS) - The Globe and Mail
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):